Parkinson's Awareness Month 2024
Helping people with Parkinson’s disease to get the best treatment possible, improving their quality of life.
April marks Parkinson’s Awareness Month, a time dedicated to increasing awareness about and elevating the conversation around Parkinson's disease, a neurological disorder that progressively impairs movement and function, affecting millions worldwide. Parkinson’s Awareness Month serves also as a time to acknowledge the tremendous strength and resilience of people living with the disease and to celebrate the contributions of researchers, healthcare professionals, companies developing therapies, family members, friends, and advocates who are supporting efforts to find effective treatments and improve Parkinson’s disease care.
Named after James Parkinson, who first identified its symptoms in 1817, Parkinson’s disease is a progressive neurodegenerative condition caused by a loss of dopamine-producing neurons in parts of the brain responsible for movement. The primary symptoms are tremors, slowness of movement, muscle rigidity, and balance problems. In addition, there are also other symptoms such as depression, changes in sleep, and dementia. The disease can have a significant impact on a person’s ability to function and their quality of life.
Due to an increased life expectancy, Parkinson’s disease is the fastest-growing neurological disorder in the world – affecting people of all races and cultures. Currently, there are 10 million diagnosed patients globally and the number is estimated to grow up to 25 million by 2050. In Finland and Germany, Parkinson's disease occurs in around 1% of people over 60 years. The number of patients affected is estimated at around 400,000 in Germany and over 15,000 in Finland.
While there are currently no treatments that can stop or slow the disease, there are drugs and therapies available to manage the symptoms. However, there is a lack of accurate and objective data regarding the patient’s motor symptoms over a longer period of time, especially within the home environment. Therapy planning is often based on subjective, short-time observation of patients during a clinic appointment.
At Adamant Health, our vision is to enable people with Parkinson’s disease and other movement disorders to live full and independent lives, symptom-free. Our unique CE-marked data-analysis technology based on surface electromyography (EMG) and motion measurement is able to measure both the visible and invisible motor symptoms of Parkinson's disease providing detailed and accurate symptom data, essential for personalized treatment that can be continuously optimized.
By enabling data-driven disease management we are supporting clinicians in making better treatment decisions for their patients and helping patients to get the best treatment possible, improving their quality of life.
Read more about our technology and service.
